NETRI SELECTED FOR THE MERCK DIGITAL SCIENCES STUDIO (MDSS) INNOVATION PROGRAM.
This initiative led by Merck Sharp & Dohme (known as MSD outside the United States and Canada) aims to support startups developing innovative technologies for biomedical research and digital health.
As a Startup Ally, NETRI, a French TechBio company specializing in organs-on-chip technologies coupled with AI and predictive biological models, joins the MDSS ecosystem as a growth-stage company contributing through engagement with MSD experts, participation in ecosystem activities, and knowledge sharing with earlier-stage startups. Startup Allies serve as role models and emerging leaders within the MDSS ecosystem, contributing through engagement, knowledge sharing, and support to earlier-stage teams.
This selection provides NETRI with the opportunity to join an international innovation ecosystem bringing together startups, scientists and industry experts to accelerate the development of new approaches for biomedical research and drug discovery.
A program dedicated to next-generation biomedical technologies.
The MDSS is an acceleration program designed for startups developing digital and biological technologies for drug discovery and development. Selected companies gain privileged access to a network of experts, mentoring sessions, and MSD’s scientific and industrial ecosystem.
For NETRI, participation in the program represents a strategic opportunity to connect its AI-enabled organ-on-chip technologies for biological data analysis with the needs of the pharmaceutical industry.
“Being selected for the MDSS as a Startup Ally is a strong recognition of NETRI’s scientific and technological relevance. This program will allow us to engage with leading experts at MSD and strengthen collaborations with key players in pharmaceutical development,” said Thibault Honegger, CEO and Co-founder of NETRI.
Accelerating innovation in biological modeling and predictive medicine.
NETRI develop platforms combining microfluidics, biology and digital technologies with data analysis to create predictive human biological models aimed at improving preclinical research.
By joining the MDSS program ecosystem, NETRI will benefit from exchanges with scientific, technological and strategic experts from MSD, facilitating connections with influential decision-makers and leading industrial partners.
This dynamic will enable the exploration of new collaboration opportunities around the use of advanced biological models for pharmaceutical research.